Tat-induced crispr/endonuclease-based gene editing
AssigneeTemple University of the Commonwealth System of Higher Education
InventorKamel Khalili
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for Tat-inducible expression of a CRISPR-associated endonuclease by a truncated HIV LTR promoter containing at least a core region and a TAR region of a HIV LTR promoter. The compositions may be used as a therapeutic treatment for the treatment and/or prevention of HIV.
Claims26
A method of inactivating a human immunodeficiency virus (HIV) in vivo or in vitro, the method comprising administering to a subject or contacting a mammalian cell with a composition comprising an isolated nucleic acid sequence encoding a clustered regularly interspaced short palindromic repeats (CRISPR)-associated endonuclease operably linked to a truncated HIV long terminal repeat (LTR) promoter containing at least a core region and a trans activation response element (TAR) of a HIV LTR promoter.
-10. (canceled)
-18. (canceled)
An isolated nucleic acid sequence comprising a sequence encoding a clustered regularly interspaced short palindromic repeats (CRISPR)-associated endonuclease operably linked to a truncated a human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter containing at least a core region and a trans activation response element (TAR) of a HIV LTR promoter.
-28. (canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising a nucleic acid sequence encoding a clustered regularly interspaced short palindromic repeats (CRISPR)-associated endonuclease operably linked to a truncated human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter containing at least a core region and a trans activation response element (TAR) of a HIV LTR promoter.
-91. (canceled)
Dependencies are inferred from the claim text.